FIELD: pharmaceutics.
SUBSTANCE: present invention relates to compounds of formula (I), in which one of R1a and R1b is hydrogen and the other is methyl; or R1a and R1b together form a cyclopropyl ring; R2 denotes methyl or monofluoromethyl, difluoromethyl or trifluoromethyl; R3 denotes methyl; R4 denotes hydrogen, halogen, monofluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy, monofluoromethoxy, difluoromethoxy or trifluoromethoxy; R5 denotes hydrogen, halogen, monofluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy, monofluoromethoxy, difluoromethoxy or trifluoromethoxy; R6 is hydrogen; R7 means hydrogen; and X denotes oxygen; or pharmaceutically acceptable salts thereof.
EFFECT: compound of formula (I) inhibit the transmission of PGE/EP4 signal and can be used for treating autoimmune pathologies, such as rheumatoid arthritis, multiple sclerosis, psoriasis, cancer and other; invention also relates to pharmaceutical compositions containing these compounds, and methods for using them in the case of individuals in need of treatment.
50 cl, 2 dwg, 3 tbl, 113 ex
Title | Year | Author | Number |
---|---|---|---|
DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USING THEM | 2010 |
|
RU2549551C2 |
HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | 2008 |
|
RU2479577C2 |
SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2539591C2 |
(ALPHA-SUBSTITUTED ARALKYLAMINO- AND HETEROARYLALKYLAMINO)PYRIMIDINYL- AND 1,3,5-TRIAZINYLBENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF IN TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2608742C2 |
PYRAZOLYL-SUBSTITUTED BENZENESULFONEAMIDE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF TREATMENT OF PATIENTS WITH INFLAMMATION OR INFLAMMATION-ASSOCIATED DISEASES | 1994 |
|
RU2139281C1 |
GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
CHEMICAL COMPOUNDS-759 | 2008 |
|
RU2481348C2 |
NEW COMPOUND OF BENZIMIDAZOLONE AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2803938C2 |
TYPE 1 DIACYLGLYCEROL-O-ACYLTRANSFERASE ENZYME INHIBITORS | 2008 |
|
RU2486186C2 |
Authors
Dates
2017-01-10—Published
2011-09-12—Filed